LONDON, UK / ACCESSWIRE / October 25, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for United Therapeutics Corp. (NASDAQ: UTHR), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=UTHR. The Company announced on October 23, 2017, that the US Food and Drug Administration (FDA) has approved a new inhalation device called the TD-300/A, for use with Tyvaso® (treprostinil) Inhalation Solution ("Tyvaso"). For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on UTHR. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=UTHR

TD-300/A Exemplifies United Therapeutics' Commitment to Improving the Ease of Administration of the Treprostinil Therapy

Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer (CEO) of United Therapeutics, stated that this new device is one of the examples of the Company's commitment to improving the ease of administration of the treprostinil therapy so that more patients can benefit from its medicine. The Company recently launched a new program to develop a small, metered dose inhalation device for treprostinil, and is planning to study the administration of inhaled treprostinil on an ?as needed' basis, to provide more flexibility for patients to use inhaled treprostinil.

Tyvaso is an Important Element of United Therapeutics' Continuum of Care

Michael Benkowitz, United Therapeutics' President and Chief Operating Officer (COO), expressed that Tyvaso is an important element of the Company's continuum of care, which provides a range of treprostinil therapy options across a spectrum of pulmonary arterial hypertension (PAH) patients. The launch of the TD-300/A, planned for mid-2018, will further optimize the Tyvaso therapy for patients and will reduce the rate of therapy discontinuation associated with the current nebulizer.

FDA Approved Tyvaso for PAH Treatment in July 2009

On July 30, 2009, the FDA approved Tyvaso for the treatment of PAH under a New Drug Application covering a drug-device combination product consisting of the Tyvaso drug product, as well as an ultrasonic nebulizer and accessories referred to as the Tyvaso Inhalation System. Since the launch of Tyvaso, it is the most-prescribed inhalation therapy for PAH in the United States.

About TD-300/A

TD-300/A is a device designed based on patients and physicians feedback; has a single button and an interface for adjusting breath counts; and has a color, graphical display that helps patients through the inhalation process. It also displays time since the last treatment and has an internal, rechargeable battery.

About Tyvaso

Tyvaso is a prescription medicine used in adults to treat PAH so as to improve exercise ability. Tyvaso can improve exercise ability in people who also take bosentan or sildenafil. The efficacy of Tyvaso has not been established in patients with significant underlying lung diseases, such as asthma or chronic obstructive pulmonary disease.

Tyvaso is a registered trademark of United Therapeutics. It is breathed in through mouth into lungs, and should only be used with the Tyvaso Inhalation System.

About Pulmonary Arterial Hypertension (PAH)

PAH is high blood pressure in the arteries of the lungs and the result of excess cells and platelets building up, causing the arteries to narrow, raising pressure, and decreasing the blood flow from the heart to the lungs. Over time, this causes the right side of the heart to enlarge and weaken, ultimately causing heart failure.

Last Close Stock Review

On Tuesday, October 24, 2017, the stock closed the trading session at $118.90, dropping 1.92% from its previous closing price of $121.23. A total volume of 513.15 thousand shares have exchanged hands. United Therapeutics' stock price advanced 6.35% in the previous twelve months. The stock is trading at a PE ratio of 13.86 and currently has a market cap of $5.08 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily